169 related articles for article (PubMed ID: 36622889)
1. Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies.
Draelos ZD
J Dermatolog Treat; 2023 Dec; 34(1):2166346. PubMed ID: 36622889
[TBL] [Abstract][Full Text] [Related]
2. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
Pariser D; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s18-23. PubMed ID: 18575222
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream.
Draelos Z; Tanghetti E; Werschler W; Kircik L; Angel A; Lagmay E; Guenin E
J Drugs Dermatol; 2022 Mar; 21(3):250-257. PubMed ID: 35254756
[TBL] [Abstract][Full Text] [Related]
4. Is switching retinoids a sound strategy for the treatment of acne vulgaris?
Gold LS; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s11-7. PubMed ID: 18575221
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
Thiboutot D; Arsonnaud S; Soto P
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
[TBL] [Abstract][Full Text] [Related]
7. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%.
Dosik JS; Homer K; Arsonnaud S
Cutis; 2005 May; 75(5):289-93. PubMed ID: 15984630
[TBL] [Abstract][Full Text] [Related]
8. Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies.
Dosik JS; Gilbert RD; Arsonnaud S
Skinmed; 2006; 5(5):219-23. PubMed ID: 16957432
[TBL] [Abstract][Full Text] [Related]
9. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
[TBL] [Abstract][Full Text] [Related]
10. Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream, 0.05% in subjects with healthy skin.
Dosik JS; Arsonnaud S
J Drugs Dermatol; 2007 Jun; 6(6):632-8. PubMed ID: 17668529
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel.
Queille-Roussel C; Poncet M; Mesaros S; Clucas A; Baker M; Soloff AM
Clin Ther; 2001 Feb; 23(2):205-12. PubMed ID: 11293554
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
[TBL] [Abstract][Full Text] [Related]
13. Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.
Kircik LH; Green L; Guenin E; Khalid W; Alexander B
J Dermatolog Treat; 2022 Jun; 33(4):2241-2249. PubMed ID: 34459694
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
[TBL] [Abstract][Full Text] [Related]
15. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
Kakita L
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S51-4. PubMed ID: 10898831
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
[TBL] [Abstract][Full Text] [Related]
17. Adapalene: a review of its use in the treatment of acne vulgaris.
Waugh J; Noble S; Scott LJ
Drugs; 2004; 64(13):1465-78. PubMed ID: 15212561
[TBL] [Abstract][Full Text] [Related]
18. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
Shalita A; Miller B; Menter A; Abramovits W; Loven K; Kakita L
J Drugs Dermatol; 2005; 4(2):153-8. PubMed ID: 15776771
[TBL] [Abstract][Full Text] [Related]
19. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents.
Brand B; Gilbert R; Baker MD; Poncet M; Greenspan A; Georgeian K; Soloff AM
J Am Acad Dermatol; 2003 Sep; 49(3 Suppl):S227-32. PubMed ID: 12963899
[TBL] [Abstract][Full Text] [Related]
20. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
Cook-Bolden FE; Gold MH; Guenin E
J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
